{"link": "http://hdl.handle.net/10138/45213", "subject": "farmasia', 'farmasia", "wordcount": 21541, "major": "The effect of systemically and locally administered clodronate on bone quality", "abstract": "The effect of systemically and locally administered clodronate on bone quality \\n\\nThe aims of this study were to evaluate the effect of clodronate, given systemically or locally, on the quality of bone and to develop a combination product including clodronate and bioactive glass for local administration in the treatment of periodontitis. The beneficial effects of clodronate on bone are known. Clodronate inhibits osteoclasts in bone and reduces bone turnover. It is used in breast cancer patients with non-osseous metastases to reduce the osteolytic complications and bone metastases. It is widely investigated e.g., in healthy women reducing bone loss. The first aim of this thesis was to investigate whether these established effects are similar in women with primary operable breast cancer. \\n\\nSince skeletal bone loss and alveolar bone loss in periodontitis share common mechanisms, the effect of clodronate upon dental application was of interest. Systemic bone conditions impact the periodontium and systemically administered clodronate positively affects the peridontium, but also side effects such as diarrhea, rash and osteonecrosis of the jaw can be problematic. However, clodronate is poorly absorbed from gastrointestinal (GI) tract and the oral bioavailability of clodronate is low. Therefore, systemically administered oral dose of clodronate needs to be high to achieve a therapeutic effect, which in turn leads to increased adverse events. Therefore, the challenge in developing novel drug delivery systems for clodronate is to achieve improved bioavailability and safety. The aim of the second part of this thesis was to develop a new delivery system that would reach the target site in the periodontium, while limiting unwanted side effects and reducing the required dose through local administration. \\n\\nIn the first part of this study, the loss of bone mineral density (BMD) was studied in patients with primary operable breast cancer given either clodronate or placebo. Oral clodronate appears to reduce the loss of bone in these patients. In premenopausal patients clodronate significantly reduced the loss of bone after one year and in postmenopausal patients clodronate increased the spinal BMD. Patients receiving clodronate had significantly more incidences of diarrhea than those receiving placebo. This indicates that clodronate is poorly absorbed from GI tract thus causing irritation to the intestine. In addition, the development of bone metastases was compared with patients with primary operable breast cancer given either clodronate or placebo. Clodronate given to these patients was shown to reduce the occurrence of bone metastases. Additionally, there was a significant reduction in mortality. \\n\\nIn the second part of the study, a novel combination product of bioactive glass (BAG, SiO2 53%, Na2O 23%, CaO 20% and P2O5 4% (w/w %)) and clodronate was investigated. Firstly, preformulation studies were performed. Clodronate was found to promote the activity of the BAG and a calcium clodronate precipitate formed. Additionally, the bioactivity lasted longer in the combination product than in BAG alone. The optimal ratio for bioactive glass and clodronate and optimal particle size for BAG for local treatment of periodontitis was investigated and selected based on bioactivity of the BAG, safest pH profile of the combination product, as well as highest possible amount of clodronate to achieve the enhanced bioactivity for the BAG. The combination product chosen was 1 g BAG with a particle size of 0.5-0.8 mm and 200 mg of clodronate premoisturized with saline. \\n\\nFinally, the selected combination product was compared to the BAG alone in the treatment of the periodontitis maintenance phase in a pilot study with ten study subjects. Based on the clinical signs and symptoms of inflammation or infection at the site (evaluated by the investigator) and overall satisfaction the combination product is at least as good as bioactive glass alone. Of the two bone remodeling biomarkers (osteoprotegerin and osteocalcin) selected for the study, only osteoprotegerin data indicate that the effect of the novel combination product is beneficial. Osteoprotegerin levels decreased in both combination product and BAG alone treated teeth but less in the combination product treated teeth. However, due to the short time period of investigation as well as the limited number of subjects and treated teeth, the result for bone quality remains only indicative. The positive effect of the combination product on tooth sensitivity may bring additional benefits in comparison to the use of BAG alone in periodontal maintenance therapy.', 'Systeemisesti ja paikallisesti annostellun klodronaatin vaikutus luun laatuun \\n\\nTutkimukseni ensimm\u00e4isess\u00e4 osassa tutkittiin systeemisesti annostellun klodronaatin luustovaikutuksia rintasy\u00f6p\u00e4potilailla. Klodronaatin tiedettiin mm. v\u00e4hent\u00e4v\u00e4n luuet\u00e4pes\u00e4kkeiden syntymist\u00e4 rintasy\u00f6p\u00e4potilailla, joilla oli et\u00e4pes\u00e4kkeit\u00e4 muualla kuin luussa. Tutkimuksessa selvitettiin, oliko klodronaatin suotuisa vaikutus luuhun n\u00e4ht\u00e4viss\u00e4 my\u00f6s rintasy\u00f6p\u00e4potilailla, joilla ei ole et\u00e4pes\u00e4kkeit\u00e4. Tutkimus oli yli 1000 rintasy\u00f6p\u00e4potilaan kansainv\u00e4linen tutkimus, joka toteutettiin l\u00e4\u00e4keteollisuuden my\u00f6t\u00e4vaikutuksella. \\n\\nTutkimustulosten perusteella primaari rintasy\u00f6p\u00e4\u00e4 sairastavat potilaat hy\u00f6tyv\u00e4t suun kautta annostellusta klodronaattihoidosta (1600 mg per p\u00e4iv\u00e4) paitsi luun tiheyden laskun estymisen my\u00f6s luuet\u00e4pes\u00e4kkeiden v\u00e4hentymisen seurauksena. Kyseinen tulos on selke\u00e4 ja havaittavissa klodronaattihoidon aikana sek\u00e4 pre- ett\u00e4 postmenopausaalisilla rintasy\u00f6p\u00e4potilailla. Klodronaattihoidon loputtua sen teho luuet\u00e4pes\u00e4kkeiden estoon n\u00e4ytt\u00e4isi h\u00e4vi\u00e4v\u00e4n, kun taas suotuisa vaikutus kuolleisuuteen tuli esiin vasta seurantajaksolla. Suun kautta annosteltuna klodronaatti oli ripulin esiintymist\u00e4 lukuun ottamatta hyvin siedetty ja turvallinen hoito. \\n\\nTutkimukseni toisessa osassa tutkittiin klodronaatin ja bioaktiivisen lasin yhdistelm\u00e4\u00e4 ja sen luustovaikutuksia periodontiitin jatkohoidossa hammasluuhun. Valmisteen ominaisuuksia analysoitiin erilaisin tavoin mm. spektroskooppisin menetelmin. Yhdistelm\u00e4valmisteessa klodronaatin todettiin edist\u00e4v\u00e4n lasin bioaktiivisuutta ja lis\u00e4ksi muodostui kalsiumklodronaattia. Bioaktiivisen lasin aktiivisuus s\u00e4ilyi kauemmin yhdistelm\u00e4valmisteessa kuin bioaktiivisessa lasissa yksin\u00e4\u00e4n. Tutkituista yhdistelmist\u00e4 kombinaatio, jossa oli 1 g bioaktiivista lasia (partikkelikokoa 0.5-0.8 mm) ja 200 mg klodronaattia todettiin olevan lasin bioaktiivisuuden kannalta paras. \\n\\nValitun yhdistelm\u00e4valmisteen vaikutusta hammasluuhun sek\u00e4 tutkimushenkil\u00f6iden raportoimia tuntemuksia hoidon aikana tutkittiin periodontiitin jatkohoidossa pienell\u00e4 kymmenen tutkimushenkil\u00f6\u00e4 k\u00e4sitt\u00e4v\u00e4ll\u00e4 tutkimuksella. Kombinaatiota verrattiin bioaktiiviseen lasiin paikallisesti annosteltuna. Muun muassa kliinisten oireiden ja tutkimushenkil\u00f6iden kokeman hoitotyytyv\u00e4isyyden perusteella yhdistelm\u00e4valmisteen todettiin olevan v\u00e4hint\u00e4\u00e4n yht\u00e4 hyv\u00e4 kuin bioaktiivisen lasin yksin\u00e4\u00e4n. Luunaineenvaihduntaa kuvaava osteoprotegerin v\u00e4heni molempien hoitojen vaikutuksesta. Yhdistelm\u00e4valmisteen todettiin kuitenkin v\u00e4hent\u00e4v\u00e4n bioaktiivista lasia enemm\u00e4n hampaiden herkkyytt\u00e4 ulkoiselle \u00e4rsykkeelle. Klodronaatti yhdess\u00e4 bioaktiivisen lasin kanssa vaikuttaa hy\u00f6dylliselt\u00e4 periodontaalisen sairauden hoidossa.", "faculty": "farmasia", "charcount": 121738, "commonwords": [["bone", 377], ["clodronate", 269], ["al", 170], ["et", 168], ["glass", 133], ["cancer", 125], ["bioactive", 124], ["bag", 118], ["combination", 100], ["study", 98], ["treatment", 97], ["patients", 83], ["product", 74], ["breast", 68], ["effect", 66], ["loss", 63], ["calcium", 58], ["formation", 57], ["periodontitis", 53], ["bisphosphonates", 52]], "keywords": "", "unit": "farmasian tiedekunta', 'Helsingfors universitet, farmaceutiska fakulteten', 'University of Helsinki, Faculty of Pharmacy, Division of Pharmaceutical Chemistry and Technology, Formulation and Industrial Pharmacy Unit", "status": "doctor", "thesistype": "V\u00e4it\u00f6skirja (artikkeli)', 'Doctoral dissertation (article-based)', 'Doktorsavhandling (sammanl\u00e4ggning)', 'Text", "pagecount": 69, "title": "The effect of systemically and locally administered clodronate on bone quality', 'Systeemisesti ja paikallisesti annostellun klodronaatin vaikutus luun laatuun", "language": "en", "author": "Rosenqvist, Kirsi", "date": "2014-05-23", "distinctwords": 4193}